Phase 2 Lymphoma Trial, Recruiting (NCT06176729)

Phase 2 Lymphoma Trial, Recruiting NCT06176729 Sponsor: Yan Zhang, MD Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT06176729 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have chosen to take part in the study and have signed a consent form agreeing to participate
People who have been diagnosed with a specific type of blood cancer called DLBCL (Diffuse Large B-Cell Lymphoma), confirmed by a laboratory tissue test, and who have not yet received any treatment for it (taking steroids alone does not count as a prior treatment)
People aged 70 or older who have been assessed as "unfit" or "frail" through a detailed health and aging assessment
People whose organs (such as heart, liver, and kidneys) and bone marrow are functioning at an adequate level, as determined by the trial site

Who may not be able to join:

People who have another type of cancer in addition to lymphoma
People who have an active Hepatitis B virus (HBV) infection
People who have an unstable or serious ongoing health condition, including (but not limited to) an active infection (other than a minor local one), or serious heart, liver, kidney, or metabolic disease that requires treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yan Zhang, MD, Peking Union Medical College Hospital

Phone: +86 13810131294

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06176729

Sponsor: Yan Zhang, MD

Phase: Phase 2

Status: Recruiting

Condition: Lymphoma

Trial contact: +86 13810131294

More information: https://clinicaltrials.gov/study/NCT06176729

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have chosen to take part in the study and have signed a consent form agreeing to participate
People who have been diagnosed with a specific type of blood cancer called DLBCL (Diffuse Large B-Cell Lymphoma), confirmed by a laboratory tissue test, and who have not yet received any treatment for it (taking steroids alone does not count as a prior treatment)
People aged 70 or older who have been assessed as "unfit" or "frail" through a detailed health and aging assessment
People whose organs (such as heart, liver, and kidneys) and bone marrow are functioning at an adequate level, as determined by the trial site

Who may not be able to join:

People who have another type of cancer in addition to lymphoma
People who have an active Hepatitis B virus (HBV) infection
People who have an unstable or serious ongoing health condition, including (but not limited to) an active infection (other than a minor local one), or serious heart, liver, kidney, or metabolic disease that requires treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Yan Zhang, MD

Registry

ClinicalTrials.gov

Start date

24 October 2023

Est. completion

24 October 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

complete remission rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov